{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:09:31Z","timestamp":1775063371790,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.humpath.2021.01.006","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T17:49:41Z","timestamp":1612460981000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Double expressor and double\/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes"],"prefix":"10.1016","volume":"111","author":[{"given":"Marco","family":"Lucioni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-506X","authenticated-orcid":false,"given":"Carlo","family":"Pescia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-0727","authenticated-orcid":false,"given":"Arturo","family":"Bonometti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8185","authenticated-orcid":false,"given":"Sara","family":"Fraticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ramponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-7008","authenticated-orcid":false,"given":"Roberta","family":"Riboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Roccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-6142","authenticated-orcid":false,"given":"Giuseppina","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-8387","authenticated-orcid":false,"given":"Gaia","family":"Goteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Paulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2021.01.006_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2021.01.006_bib2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.01.006_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.01.006_bib4","series-title":"WHO classification of skin tumours","author":"Elder","year":"2018"},{"key":"10.1016\/j.humpath.2021.01.006_bib5","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.865","article-title":"Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: comparison with current classification and definition of prognostic markers","volume":"5","author":"Lucioni","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.humpath.2021.01.006_bib6","first-page":"275","article-title":"Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type\u202f: clinical, morphologic and prognostic differences","volume":"17","author":"Felcht","year":"2019","journal-title":"JDDG"},{"key":"10.1016\/j.humpath.2021.01.006_bib7","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.01.006_bib8","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","article-title":"MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma","volume":"136","author":"Menguy","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.humpath.2021.01.006_bib9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.humpath.2021.01.006_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","article-title":"Double-hit lymphomas: current paradigms and novel treatment approaches","volume":"1","author":"Dunleavy","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.humpath.2021.01.006_bib11","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2021.01.006_bib12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41379-018-0041-7","article-title":"Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas","volume":"31","author":"Menguy","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2021.01.006_bib13","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000001132","article-title":"High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Schrader","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.01.006_bib14","series-title":"Annals of oncology\u202f: official journal of the European society for medical oncology","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","author":"Younes","year":"2017"},{"key":"10.1016\/j.humpath.2021.01.006_bib15","first-page":"12","article-title":"Primary cutaneous B cell lymphomas","volume":"10","author":"Kempf","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.humpath.2021.01.006_bib16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/his.13832","article-title":"Primary cutaneous large B-cell lymphomas: relevance of the 2017 WHO classification","volume":"74","author":"Menguy","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.01.006_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","article-title":"Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas","volume":"123","author":"Hallermann","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.humpath.2021.01.006_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3324\/haematol.2009.007203","article-title":"Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP","volume":"95","author":"Shustik","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2021.01.006_bib19","first-page":"530","article-title":"BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies","volume":"10","author":"Li","year":"2019","journal-title":"J Canc"},{"key":"10.1016\/j.humpath.2021.01.006_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2133.2001.04128.x","article-title":"Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma","volume":"144","author":"Child","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2021.01.006_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","article-title":"Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma","volume":"24","author":"Dijkman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.01.006_bib22","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.01.006_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.01.006_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.humpath.2021.01.006_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.01.006_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/modpathol.2017.134","article-title":"Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"31","author":"Miyaoka","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2021.01.006_bib27","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2021.01.006_bib28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/his.12884","article-title":"MYC\/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis","volume":"68","author":"Li","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.01.006_bib29","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2018.195958","article-title":"MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients","volume":"104","author":"Ambrosio","year":"2019","journal-title":"Haematologica"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:38:10Z","timestamp":1758645490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817721000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S0046817721000125"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2021.01.006","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double expressor and double\/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2021.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}